A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer

Veure altres versions (1)

Dades bibliogràfiques
Autors principals:	Brunner, T, Geiger, M, Grabenbauer, G, Mantoni, T, Cavallaro, A, Hohenberger, W, McKenna, G, Sauer, R
Format:	Conference item
Publicat:	2008

Ítems similars

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
per: Brunner, T, et al.
Publicat: (2008)

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
per: Brunner, T, et al.
Publicat: (2008)

ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
per: Wilson, J, et al.
Publicat: (2016)

Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation.
per: Tinkl, D, et al.
Publicat: (2009)

The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells
per: Al-Assar, O, et al.
Publicat: (2016)

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
per: Unaí Tupinambás, et al.

Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.
per: Golcher, H, et al.
Publicat: (2008)

New insights into the in silico prediction of HIV protease resistance to nelfinavir.
per: Dinler A Antunes, et al.
Publicat: (2014-01-01)

Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
per: Brunner, T, et al.
Publicat: (2008)

Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir
per: Chao Ying, et al.
Publicat: (2008-02-01)

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial
per: Mukherjee, S, et al.
Publicat: (2024)

Predicting Respiratory Motion for Patients Undergoing Pancreatic Chemoradiation in the Absence of Volumetric Motion Imaging
per: Eccles, C, et al.
Publicat: (2010)

Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma.
per: Mantoni, T, et al.
Publicat: (2008)

Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma
per: Mantoni, T, et al.
Publicat: (2008)

The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response
per: Anjali K. Gupta, et al.
Publicat: (2007-04-01)

Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.
per: Pranav Kumar, et al.
Publicat: (2010-03-01)

Dosimetric parameters predict toxicity in chemoradiotherapy with nelfinavir for pancreatic cancer
per: Holyoake, D, et al.
Publicat: (2016)

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein
per: Zhongli Liu, et al.
Publicat: (2022-08-01)

Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial
per: Sudeep Gupta, et al.
Publicat: (2022-04-01)

The Interaction of pancreatic Cancer and Stellate Cells as a Mediator of Radiation Resistance in ductal Pancreatic Adenocarcinoma
per: Mantoni, T, et al.
Publicat: (2011)

The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors
per: André FA Santos, et al.
Publicat: (2011-03-01)

ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
per: Wilson, J, et al.
Publicat: (2017)

PREOPERATIVE CHEMORADIATION FOR RESECTABLE ADENOCARCINOMA OF THE PANCREAS (ISRCTN 78805636): PATTERN OF RECURRENCE.
per: Golcher, H, et al.
Publicat: (2012)

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component
per: Mukherjee, S, et al.
Publicat: (2018)

Predicting Respiratory Motion for Patients Undergoing Pancreatic Chemoradiation in the Absence of Volumetric Motion Imaging
per: Eccles, C, et al.
Publicat: (2010)

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
per: Christoph Driessen, et al.
Publicat: (2016-03-01)

Nelfinavir and Non-Nucleoside Reverse Transcriptase Inhibitor-Based Salvage Regimes in Heavily Hiv Pretreated Patients
per: Jean-Guy Baril, et al.
Publicat: (2003-01-01)

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo
per: Steffi Liebscher, et al.
Publicat: (2017-02-01)

ATR targeting by the novel inhibitor VE-822 selectively sensitizes pancreatic cancer cells and tumors to radiation and chemoradiation
per: Fokas, E, et al.
Publicat: (2013)

Chemoradiation of pancreatic carcinoma
per: Erdinç Nayır, et al.
Publicat: (2016-08-01)

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo
per: Camille Bono, et al.
Publicat: (2012-07-01)

Tumor stroma interaction and radiation resistance in pancreatic cancer
per: Mantoni, T, et al.
Publicat: (2011)

Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer
per: Hill, E, et al.
Publicat: (2016)

Spectrophometric Determination of Nelfinavir Mesylate
per: K. Vanitha Prakash, et al.
Publicat: (2006-01-01)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
per: V. B. Denisenko,, et al.
Publicat: (2018-12-01)

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study
per: Alison K. Yoder, et al.
Publicat: (2021-07-01)

Down-regulation of Akt signaling with HIV-1 protease inhibitors
per: Gupta, A, et al.
Publicat: (2005)

Progress towards the use of HIV protease inhibitors in cancer therapy
per: Bernhard, E, et al.
Publicat: (2008)

Progress towards the use of HIV protease inhibitors in cancer therapy.
per: Bernhard, E, et al.
Publicat: (2008)

Pancreatic stellate cells modify tumour growth and radioresponse of pancreatic cancer
per: Lunardi, S, et al.
Publicat: (2010)